Vnitr Lek 2007, 53(5):509-511

Surgical treatment of diabetic retinopathy

V. Korda
Oční klinika Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Pavel Rozsíval, CSc.

Laser treatment is effective for diabetic macular oedema and proliferative diabetic retinopathy. In focal diabetic macular oedema, laser coagulation of the microaneurisms prevents the leakage of liquid through their walls. In diffuse macular oedema, laser photocoagulation not only destroys the microaneurisms but probably also hereby causes stimulation of proliferation activity of endothelial cells in retinal capillaries and veins. For some patients with diabetic retinopathy there is a progression of retinal findings and complications arise that require surgery within the eye - pars plana vitrectomy (PPV). In general PPV is indicated in diabetic retinopathy in the following cases: vitreous opacity, traction disorders.

Keywords: diabetic retinopathy; laser panretinophotocoagulation; argon laser; diabetic macular oedema; pars plana vitrectomy

Received: June 2, 2006; Published: May 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Korda V. Surgical treatment of diabetic retinopathy. Vnitr Lek. 2007;53(5):509-511.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabeties. Ophthalmology 1989; 96: 255-264. Go to original source... Go to PubMed...
    2. Klein R et al. The Wisconsin Epidemiologie Study of Diabetic Retinopathy. VI. Retinal photocoagulation. Ophthalmology 1987; 94: 747-753. Go to original source... Go to PubMed...
    3. Murphy PR, Egbert PR. Regression of iris neovascularization following panretinal photocoagulation. Arch Ophthalmol 1979; 97: 700-702. Go to original source... Go to PubMed...
    4. Ooft BH, Blankenship GW. Single versus multiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1982; 89: 772-779. Go to original source... Go to PubMed...
    5. Sinclair SH, Nesler C, Foxman B. Macular edema and pregnancy in insulin-dependent diabetes. Am J Ophthalmol 1984; 97: 154-167. Go to original source... Go to PubMed...
    6. Olk RJ. Argon green (514 nm) versus krypfon red (647 nm) modified grid laser photocoagulation for diffuse Diabetic macular edema. Ophthalmology 1990; 97: 1101-1113. Go to original source... Go to PubMed...
    7. Early Treatment Diabetic Retinopathy Study Researeh Group. Photocoagulation for diabetic macular edema. ETDRS Report No. 1. Arch Ophthalmol 1985; 103: 1796-1806. Go to original source...
    8. Abrams GW. En bloc dissection techniques in vitrectomy for diabetic retinopathy. In: Lewis H, Ryan SJ (eds). Medical and surgical retina: advances, controversies, and management. St. Louis: Mosby; 1994: 304-320. Abrams GW, Williams GA. En bloc excision of diabetic membranes. Am J Ophthalmol 1987; 103: 302. Go to original source...
    9. McLeod D. Entry site neovascularization after diabetic vitrectomy. Br J Ophthalmol 2000; 84: 810-811. Go to original source... Go to PubMed...
    10. Eliott O Outcome of vitrectomy for dense, premacular, subhyaloid hemorrhage secondary to proliferative diabetie retinopathy. In: Retina Society/Vitreous Society annual meeting - the combined meeting. San Francisco, CA: 2002.
    11. Steinberg PJ, Aguilar HE, Drews C et al. The effect of tissue plasminogen activator on retinal bleeding. Arch Ophthalmol 1990; 108: 720. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.